GEA
ANIP icon

Glen Eagle Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Glen Eagle Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-150
Closed -$9.67K – 683
2017
Q4 		$9.67K Hold
150
– – 0.01% 435
2017
Q3 		$7.87K Buy
150
+50
+50% +$2.38K 0.01% 467
2017
Q2 		$4.68K Hold
100
– – ﹤0.01% 482
2017
Q1 		$4.95K Buy
+100
New +$5.62K ﹤0.01% 460

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Glen Eagle Advisors's ANIP Position: Q1 2018 in Review

Glen Eagle Advisors sold out of ANI Pharmaceuticals (ANIP) in Q1 2018, closing a stake of 150 shares — an estimated $9.67K sold.

Glen Eagle Advisors first reported a position in ANIP in Q1 2017 and held it in 4 quarters. The position peaked at $9.67K in Q4 2017. 175 funds tracked by Wall St. Rank hold ANIP as of Q1 2018.

  • Glen Eagle Advisors reported no remaining ANI Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Glen Eagle Advisors sold 150 ANI Pharmaceuticals shares in Q1 2018, an estimated $9.67K.
  • Glen Eagle Advisors first reported a position in ANI Pharmaceuticals in Q1 2017 and held it in 4 quarters.
  • Glen Eagle Advisors's ANI Pharmaceuticals position peaked at $9.67K in Q4 2017.
  • 175 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2018.

Based on Glen Eagle Advisors's 13F filing for Q1 2018, filed 13 Aug 2024.